Project description DEENESFRITPL New database to help treat type 2 diabetes Type 2 diabetes is the most common type of diabetes, accounting for around 90 % of all cases. It is most commonly diagnosed in older adults, but is increasingly being seen in children, adolescents and younger adults due to rising levels of obesity, physical inactivity and poor diet. Delivering high-quality patient-centred care and a personalised approach to disease management is necessary. The EU-funded EASY-Diabetes project is developing a digital health solution to ensure patients receive the most appropriate therapy. Its software-as-a-service works by providing healthcare providers access to a curated global database of clinical data and medical evidence collected over the course of nine years. Powered by machine learning algorithms and artificial intelligence, the project is preparing its go-to-market strategy. Show the project objective Hide the project objective Objective EASY – Diabetes is a digital health solution that helps patients with Type 2 diabetes and health care providers analyse dataand make better decisions about therapies by accessing a carefully curated global database based on clinical data andmedical evidence collected over the course of nine years and powered by machine learning algorithms and other forms ofartificial intelligence. We offer EASY-Diabetes as a Software-as-a-Service to healthcare providers at a fee of €50 per patientper year.Diabetes is a prevalent and costly chronic disease, affecting 425 million people worldwide. Although 9.2% of the health carebudget in Europe spent on diabetes, the results for patients remain inadequate even in the most advanced healthcaresystems. Patients lack a patient-centred and personalised approach to disease management. 90% of patients with T2D aretreated by GPs in primary care. Most clinics lack both the manpower and the expertise required to deal with the needs ofpatients for regular contact with health care providers and the complexity of diabetes treatment. Existing eHealth solutionsshow some crucial drawbacks, such as lack of clinical validation against the standard of care, no personalised medicaltreatment options, not being drug agnostic.Our team brings together demonstrated expertise in medicine, clinical trials, drug development, regulatory affairs, productdevelopment, programming, machine learning, business development.The SME Phase 1 Feasibility study will aim to complete the validation of the commercial feasibility of Easy – Diabetes withtarget market segments and key stakeholders. We will strengthen our financial planning and IP protection strategynecessary to improve our service and refine our go-to-market strategy. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health scienceshealth scienceshealth care serviceseHealthnatural sciencescomputer and information sciencesdatabasesmedical and health sciencesclinical medicineendocrinologydiabetesnatural sciencescomputer and information sciencesartificial intelligencemachine learning Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator ADJUVIA AB Net EU contribution € 50 000,00 Address Trollebergsvagen 13 22229 Lund Sweden See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Södra Sverige Sydsverige Skåne län Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00
